Faculty Articles

Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome

Publication Title

Biological Psychiatry

ISSN

0006-3223

Publication Date

11-1-1992

Abstract

Chronic fatigue syndrome (CFS) includes many symptoms of major depression. For this reason, many antidepressants have been used to treat the symptoms of this disorder. Among the more recently released antidepressants are fluoxetine and bupropion. In this open study, nine CFS patients who either could not tolerate or did not respond to fluoxetine showed significant response when administered 300 mg/day of bupropion for an 8-week period in both rating of HDRS (t = 4.80, p < 0.01) and BDI (t = 2.48, p < 0.05). Furthermore, bupropion improvement in Hamilton Depression Rating Scale correlated significantly with change in plasma homovanillic acid (HVA) (r = 0.96, p < 0.01). Plasma total methylhyroxyphenolglycol (MHPG) also increased significantly during bupropion treatment (t = 2.37, p = 0.05). Measures of T1 microsomal antibodies also decreased over treatment time; increases in natural killer cell numbers correlated inversely with change in plasma levels of free MHPG (r = −0.88, p < 0.05). Bupropion responders were more likely to have trough blood levels above 30 ng/ml (X2 = 3.6, p = 0.05).

DOI

10.1016/0006-3223(92)90087-G

Volume

32

Issue

9

First Page

834

Last Page

838

Disciplines

Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy

This document is currently not available here.

Peer Reviewed

Find in your library

Share

COinS